Arcus Biosciences RCUS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $222M+48.0% | $150M+18.1% | $127M-38.3% | $206M+39.2% | ||
| $759M-8.3% | $828M+31.0% | $632M-21.3% | $803M+129% | ||
| —— | —— | —— | —— | ||
| $11M-45.0% | $20M-47.4% | $38M-2.6% | $39M-94.8% | ||
| $5M0.0% | $5M+25.0% | $4M0.0% | $4M+79.6% | ||
| $1.01B-0.9% | $1.02B+22.3% | $831M-22.1% | $1.07B-15.5% | ||
| $40M-14.9% | $47M-7.8% | $51M+45.7% | $35M+9.4% | ||
| $63M-13.7% | $73M-31.1% | $106M-7.0% | $114M-1.7% | ||
| $29M+107% | $14M-86.9% | $107M-17.1% | $129M-29.1% | ||
| $1.14B-1.0% | $1.15B+5.0% | $1.1B-18.6% | $1.35B-15.5% | ||
| $42M+133% | $18M+5.9% | $17M-15.0% | $20M+100% | ||
| $33M-73.2% | $123M+61.8% | $76M0.0% | $76M+40.7% | ||
| $35M-58.8% | $85M-6.6% | $91M-6.2% | $97M-4.9% | ||
| $13M+8.3% | $12M+9.1% | $11M+267% | $3M-41.2% | ||
| $78M-75.5% | $319M-19.8% | $398M— | —— | ||
| $1M— | —— | —— | $0— | ||
| $18M+20.0% | $15M+400% | $3M0.0% | $3M— | ||
| $231M+2.2% | $226M+22.8% | $184M-4.7% | $193M+16.3% | ||
| $99M+106% | $48M— | $0— | —— | ||
| $135M-14.0% | $157M+10.6% | $142M+1.4% | $140M+14.8% | ||
| 400M-75.3% | 1.6B+23.3% | 1.3B+8.7% | 1.2B+7.9% | ||
| -$1.49B-31.2% | -$1.13B-33.3% | -$849M-56.6% | -$542M-97.1% | ||
| $0— | —— | $0+100% | -$7M-600% | ||
| $631M+30.1% | $485M+5.0% | $462M-29.7% | $657M-22.0% | ||
| $1.14B-1.0% | $1.15B+5.0% | $1.1B-18.6% | $1.35B-15.5% | ||
| $1.01B+1.8% | $992M+14.5% | $866M-24.4% | $1.15B— | ||
| $225M+47.1% | $153M+17.7% | $130M-37.8% | $209M+38.4% | ||
| $1.01B+1.8% | $992M+14.5% | $866M-23.9% | $1.14B— | ||
| $759M-8.3% | $828M+31.0% | $632M-21.3% | $803M+129% | ||
| $63M-13.7% | $73M-31.1% | $106M-7.0% | $114M-1.7% | ||
| $1.01B+1.8% | $992M+14.5% | $866M-24.4% | $1.15B— | ||
| $29M+107% | $14M-86.9% | $107M-17.1% | $129M-29.1% | ||
| $63M-13.7% | $73M-31.1% | $106M-7.0% | $114M-1.7% | ||
| $63M-13.7% | $73M-31.1% | $106M-7.0% | $114M-1.7% | ||
| $33M+6.5% | $31M+19.2% | $26M+4.0% | $25M— | ||
| $43M-81.6% | $234M-23.8% | $307M-13.5% | $355M-23.2% | ||
| $33M+6.5% | $31M+19.2% | $26M+4.0% | $25M— | ||
| $154M+25.2% | $123M+61.8% | $76M0.0% | $76M+40.7% | ||
| $43M-81.6% | $234M-23.8% | $307M-13.5% | $355M-23.2% | ||
| 12.9%— | —— | —— | —— | ||
| $1M-50.0% | $2M— | $0— | —— | ||
| $43M-81.6% | $234M-23.8% | $307M-13.5% | $355M-23.2% | ||
| $198M+24.5% | $159M+31.4% | $121M-4.0% | $126M+11.0% | ||
| $100M+100% | $50M— | $0— | —— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.00— | ||
| 125.3M+35.9% | 92.2M+22.1% | 75.5M+3.6% | 72.9M— | ||
| $2.12B+30.9% | $1.62B+23.3% | $1.31B+8.7% | $1.21B+7.9% | ||
| $0— | $0-100% | $1M— | $0— | ||
| $0— | $0-100% | $1M-85.7% | $7M— | ||
| 31-42.6% | 54-48.6% | 105-52.1% | 219— | ||
| $1.01B+1.8% | $992M+14.5% | $866M-24.4% | $1.15B— | ||
| $89M+36.9% | $65M+80.6% | $36M-20.0% | $45M+52.1% | ||
| $0— | $0-100% | $1M-85.7% | $7M— | ||
| $0— | $0-100% | $1M— | $0— | ||
| $1.01B+1.8% | $992M+14.5% | $866M-24.4% | $1.15B— | ||
| $1.01B+1.8% | $992M+14.5% | $866M-23.9% | $1.14B— | ||
| $1.01B+1.8% | $992M+14.5% | $866M-23.9% | $1.14B— | ||
| $225M+47.1% | $153M+17.7% | $130M-37.8% | $209M+38.4% | ||
| $00.0% | $00.0% | $00.0% | $0— | ||
| $400M0.0% | $400M0.0% | $400M0.0% | $400M— | ||
| $125.3M+35.9% | $92.2M+22.1% | $75.5M+3.6% | $72.9M— | ||
| $125.3M+35.9% | $92.2M+22.1% | $75.5M+3.6% | $72.9M— | ||
| $78M-75.5% | $319M-19.8% | $398M— | —— | ||
| $100M+100% | $50M— | $0— | —— | ||
| $1M-50.0% | $2M— | $0— | —— | ||
| $31-42.6% | $54-48.6% | $105-52.1% | $219— | ||
| $5M0.0% | $5M+25.0% | $4M0.0% | $4M+79.6% | ||
| $18M+20.0% | $15M+400% | $3M0.0% | $3M— | ||
| $10M-23.1% | $13M-56.7% | $30M+100% | $15M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $3M0.0% | $3M0.0% | $3M0.0% | $3M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arcus Biosciences's total assets?
- Arcus Biosciences (RCUS) holds $997.0M in total assets, down 13.8% year over year.
- How much debt does Arcus Biosciences have?
- Arcus Biosciences carries $113.0M in total debt against $524.0M of shareholders' equity, a debt-to-equity ratio of 0.22.
- How much cash does Arcus Biosciences have?
- Arcus Biosciences holds $201.0M in cash and equivalents.
- Can Arcus Biosciences cover its short-term obligations?
- Its current ratio is 4.04 — current assets exceed current liabilities.
- Where does Arcus Biosciences's balance sheet data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
